A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 24 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
- 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.